(TARS) – Globe Newswire
-
Tarsus to Participate at Upcoming Investor Conferences
-
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
-
Tarsus Announces Pricing of $100.0 Million Public Offering
-
Tarsus Announces Proposed $100.0 Million Public Offering
-
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
-
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
-
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
-
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
-
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
-
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
-
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
-
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
-
Tarsus to Present at Upcoming Investor Conferences
-
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
-
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
-
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
-
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
-
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
-
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
-
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
-
Tarsus to Present at the Jefferies Global Healthcare Conference
-
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
-
Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
-
Tarsus to Participate at the Bank of America 2023 Healthcare Conference
-
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
-
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
-
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
-
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
-
Tarsus to Present at Upcoming Investor Conferences
-
Tarsus to Present at Upcoming Investor Conferences
-
Tarsus Added to NASDAQ Biotechnology Index
-
Tarsus Added to NASDAQ Biotechnology Index
-
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
-
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
-
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
-
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
-
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
-
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
-
Tarsus Announces Transition Plans for Board of Directors
-
Tarsus Announces Transition Plans for Board of Directors
-
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
-
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
-
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
-
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
-
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
-
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
-
Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis
-
Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis
-
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements
-
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements
Back to TARS Stock Lookup
